Slide 1: Half Year Results 2025
HALF YEAR RESULTS 2025 ANALYST & MEDIA CONFERENCE CALL Zurich, 12 August 2025
Slide 2: Speakers
SPEAKERS M O N I C A M A N O TA S TANI A M I CKI CEO CFO 2
Slide 3: Agenda
AGENDA FINANCIAL FINANCIAL 1 AND OPERATING HIGHLIGHTS 2 RESULTS QUESTIONS 3 OUTLOOK 4 AND ANSWERS 3
Slide 4: CEO Succession
CEO SUCCESSION SHAPING THE NEXT PHASE OF SUSTAINABLE GROWTH › Monica Manotas appointed CEO, effective August 1, 2025 › 20+ years of international leadership in life sciences and laboratory products › Various executive positions at Thermo Fisher Scientific, most recently SVP & President, Life Science
Slide 5: Market Developments H1 2025
MARKET DEVELOPMENTS H1 2025 KEY TRENDS AND BUSINESS IMPACT MARKET DEVELOPMENTS TECAN › Pharma: projects realized in pre-defined growth areas; › Life Sciences Business conservative spending and slow decision-making elsewhere › Strong growth in consumables and select instruments, driven by clinical di
Slide 6: Operating Highlights H1 2025
OPERATING HIGHLIGHTS H1 2025 DRIVING OPERATIONAL RESILIENCE, INNOVATION, AND PARTNERSHIPS FURTHER ENHANCING CONTINUED INNOVATION WITH KEY PROMISING NEW PARTNERSHIPS IN OPERATIONAL RESILIENCE PRODUCT LAUNCHES PARTNERING BUSINESS › Realized benefits from cost-reduction › Commercial ramp-up of multi-om
Slide 7: Agenda
AGENDA FINANCIAL 1 AND OPERATING HIGHLIGHTS 2 FINANCIAL RESULTS QUESTIONS 3 OUTLOOK 4 AND ANSWERS 7
Slide 8: H1 2025 Order Entry and Sales Performance
H1 2025 ORDER ENTRY AND SALES PERFORMANCE ORDER ENTRY ORDER ENTRY H1 2025 472.2 458.3 › -2.9% in CHF and -0.7% in LC › Order entry improved sequentially in Q2-25 CHF (mio) › Book-to-bill ratio returned to a level of above 1 SALES H1 2025 2024 2025 › Reported sales -5.9% in CHF, -3.7% in LC SALES › S
Slide 9: H1 2025 Segment Sales
H1 2025 SEGMENT SALES LIFE SCIENCES BUSINESS › Reported sales -1.0% in CHF, +1.6% in LC › Sequential improvement: Q2 sales up low single digits (LC) vs. prior year; Q1 slightly below SEGMENT SALES › Growth supported by clinical diagnostics (esp. genomic testing) and recovering consumables 279.6 › Re
Slide 10: H1 2025 Gross Profit
H1 2025 GROSS PROFIT GROSS PROFIT (% = % OF SALES) GROSS PROFIT REACHED CHF 159.3M › CHF 1.5m below H1 2024 GROSS PROFIT MARGIN UP BY 180 BPS › Reported gross profit margin at 36.2% 160.8 159.3 Main effects explaining difference of 180 bps: › (+) Favorable product mix CHF (mio) 34.4% 36.2% › (+) Pri
Slide 11: H1 2025 Cost Structure
H1 2025 COST STRUCTURE OPERATING EXPENSES (% = % OF SALES) OPERATING EXPENSES LESS COST OF SALES › Operating expenses up CHF 1.0m, driven by higher exceptional costs; down ~5% year-on-year on a like-for-like basis › Sales & Marketing decreased, mainly due to lower performance-based 137.8m 138.8m (29
Slide 12: H1 2025 EBITDA
H1 2025 EBITDA EBITDA ADJUSTED EBITDA* REACHED CHF 65.7M › CHF 2.2m below H1 2024 CHF (mio) 67.9 65.7 59.9 54.9 ADJUSTED EBITDA MARGIN UP BY 50 BPS › Adjusted EBITDA margin increased to 15.0% (H1 2024: 14.5%) EBITDA adj. EBITDA 2024 2025 Main effects explaining difference of 50 bps: › (+) Gross prof
Slide 13: H1 2025 Segment Profitability
H1 2025 SEGMENT PROFITABILITY REPORTED EBIT (IN CHF MILLIONS) LIFE SCIENCES BUSINESS › Adj. EBITDA margin amounted to 14.0% of sales › Factors contributing include: CHF (mio) 22.5 21.1 › (-) Exchange rates 12.6 9.6 › (-) Tariffs › (+) Price increases Life Sciences Business Partnering Business › (+)
Slide 14: H1 2025 Net Profit and Earnings per Share
H1 2025 NET PROFIT AND EARNINGS PER SHARE ADJUSTED NET PROFIT ADJUSTED NET PROFIT* 36.5 › CHF 2.8m below H1 2024 33.7 Main factors contributing: › (-) EBIT CHF (mio) › (-) Tax rate increased to 22.5% (H1 2024: 20.5%) due to a constant non-cash amortization in connection with Swiss tax reform based o
Slide 15: H1 2025 Cash Flow
H1 2025 CASH FLOW CASH FLOW FROM OPERATIONS OF CHF 60.0M (H1 2024: CHF 43.4M) +101.8 -60.3 › Cash conversion improved to 109.2% of reported EBITDA (H1 2024: 72.5%) › Decreased inventories and lower accruals and provisions › Days Sales Outstanding (DSO) at 45 days (H1 2024: 51 days) +60.0 › Includes
Slide 16: Launch of Share Buyback Program
LAUNCH OF SHARE BUYBACK PROGRAM RETURNING VALUE TO SHAREHOLDERS WHILE SUPPORTING STRATEGIC GROWT H › Reflecting confidence in Tecan’s long-term growth prospects and strong financial position › Plan to repurchase registered shares with a value of up to CHF 120 million via the ordinary trading line of
Slide 17: Agenda
AGENDA FINANCIAL 1 AND OPERATING HIGHLIGHTS 2 FINANCIAL RESULTS QUESTIONS 3 OUTLOOK 4 AND ANSWERS 17
Slide 18: 2025 Financial Outlook Confirmed
2025 FINANCIAL OUTLOOK CONFIRMED KEY ASSUMPTIONS FOR 2025 GUIDANCE REMAIN LARGELY UNCHANGED SALES OUTLOOK EBITDA MARGIN OUTLOOK Sales development in LC -LSD to +LSD Adjusted EBITDA margin 17.5-18.5% of sales Assumptions: › Profitability supported by agile cost management and comprehensive cost-reduc
Slide 19: Key Takeaways
KEY TAKEAWAYS DRIVING HEALTHCARE INNOVATION AND PROFITABLE GROWTH › Well positioned to benefit from global healthcare trends › Synergistic Life Sciences Business and Partnering Business divisions › Ongoing innovation with new product launches, leading digital solutions, and new partnerships › Enhanc
Slide 20: Agenda
AGENDA. FINANCIAL 1 AND OPERATING HIGHLIGHTS 2 FINANCIAL RESULTS QUESTIONS 3 OUTLOOK 4 AND ANSWERS 20
Slide 21: PETVPEETEEEEEET EET TEE @TECAN.
PETVPEETEEEEEET EET TEE @TECAN.
Slide 22: Appendix: Reconciliation of Adjusted Consolidated Statement of Profit or Loss
APPENDIX CHF 1'000 / unaudited H1 2024 H1 2025 Sales 467’157 439’475 GAAP operating profit (EBIT) 25’974 23’143 RECONCILIATION OF ADJUSTED 33’911 31’765 CONSOLIDATED STATEMENT OF Depreciation and amortization PROFIT OR LOSS. Non-GAAP EBITDA 59’885 54’908 In % of sales 12.8% 12.5% Adjustments for Res
Slide 23: Contact & Events
CONTACT & EVENTS. CONTACT Martin Braendle Senior Vice President, Corp. Communications & IR +41 (0) 44 922 84 30 investor@tecan.com www.tecan.com KEY UPCOMING DATES October 13, 2025 Q3 2025 Qualitative Update 23
Slide 24: Scaling Healthcare Innovation Globally
SCALING HEALTHCARE INNOVATION GLOBALLY.
Slide 25: Thank You
THANK YOU. TECAN – WHO WE ARE At Tecan we are driven to improve people’s lives and health. We do this Tecan Group Ltd. makes every effort to include accurate and up-to-date by empowering our customers to scale healthcare innovation globally information, however, it is possible that omissions or erro